Skip to contentB
BIO-TECHNE Corp
B
TECHBIO-TECHNE Corp Q3 2026 · 10-Q
Revenue$311.42M$311.42M−1.5% vs Q3 2025 Net Income$51.05M$51.05M+126.0% vs Q3 2025 EPS Diluted$0.32$0.32+128.6% vs Q3 2025 Gross Profit$208,288,000−2.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BIO-TECHNE Corp · CIK 842023 · Engraved from SEC EDGAR
Operating Cash Flowderived$86,661,000+110.8% Free Cash Flowderived$77,575,000+150.3% Margins · derivedGross margin66.9%−1.0 pt vs Q3 2025
Operating margin24.2%+12.0 pt vs Q3 2025
Net margin16.4%+9.2 pt vs Q3 2025
ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end